Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 14
Submit an article Journal homepage
796
Views
0
CrossRef citations to date
0
Altmetric
Review

EGFR and KRAS Mutations, and ALK Fusions: Current Developments and Personalized Therapies for Patients with Advanced Non-Small-Cell Lung Cancer

Ramon Andrade de Mello1 Department of Medical Oncology, Portuguese Oncology Institute, Rua Dr António Bernardino de Almeida, 4200-072, Porto, Portugal;3 Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, LondonSW3 6JJ, UK;2 Department of Medicine, Faculty of Medicine, University of Porto (FMUP), Alameda Prof Hernani, Monteiro, 4200-319, Porto, Portugal. View further author information
,
Pedro Madureira4 ICBAS – Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal;5 IBMC – Instituto de Biologia Molecular e Celular, Porto, PortugalView further author information
,
Liliana S Carvalho5 IBMC – Instituto de Biologia Molecular e Celular, Porto, Portugal;6 Department of Pharmacology & Therapeutics, FMUP – Faculty of Medicine, University of Porto, Alameda Prof Hernani Monteiro, 4200-319, Porto, PortugalView further author information
,
António Araújo1 Department of Medical Oncology, Portuguese Oncology Institute, Rua Dr António Bernardino de Almeida, 4200-072, Porto, Portugal;4 ICBAS – Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, PortugalView further author information
,
Mary O‘Brien3 Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, LondonSW3 6JJ, UKView further author information
&
Sanjay Popat3 Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, LondonSW3 6JJ, UK;7 Molecular Genetics & Genomics Group, Imperial College, London, UKView further author information
Pages 1765-1777 | Published online: 05 Nov 2013

References

  • Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
  • Siegel R , NaishadhamD, JemalA. Cancer statistics, 2012. CA Cancer J. Clin.62(1), 10–29 (2012).
  • Felip E , StahelR, PavlidisN. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann. Oncol.16(Suppl. 1), i28–i29 (2005).
  • Herbst R , HeymachJ, LippmanS. Lung cancer. N. Engl. J. Med.359(13), 1367–1380 (2008).
  • Araújo A , CoelhoA, de Mello RA et al. Personalizing medicine – strategies for implementing the evaluation of ALK rearrangement in non-small-cell lung cancer in Portugal. Rev. Port. Pneumol.18(5), 244–246 (2012).
  • de Mello RA , MarquesDS, MedeirosR, AraújoAM. Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J. Clin. Oncol.2(11), 367–376 (2011).
  • Drilon A , RekhtmanN, LadanyiM, PaikP. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol.13(10), e418–e426 (2012).
  • Sharma SV , BellDW, SettlemanJ, HaberDA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer7(3), 169–181 (2007).
  • de Mello RA , PiresFS, MarquesDS et al. EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumor Biol.33(6), 2061–2068 (2012).
  • Dienstmann R , MartinezP, FelipE. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget2(3), 165–177 (2011).
  • Ebbert JO , ChhatwaniL, AubryMC et al. Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions. J. Thorac. Oncol. 5(8), 1213–1220 (2010).
  • Sculier J , ChanskyK, CrowleyJ, van Meerbeeck J, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM classification of malignant tumors and the proposals for the 7th Edition. J. Thorac. Oncol.3(5), 457–466 (2008).
  • Brundage M , DaviesD, MacKillopW. Prognostic factors in non-small cell lung cancer. Chest122(3), 1037–1057 (2002).
  • Bacchi CE , CiolH, QueirogaEM, BenineLC, SilvaLH, OjopiEB. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics (Sao Paulo).67(5), 419–424 (2012).
  • Lynch T , BellD, SordellaR et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129–2139 (2004).
  • Shepherd F , Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
  • Cappuzzo F , HirschF, RossiE et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Nat. Cancer Inst. 97(9), 643–655 (2005).
  • Marchetti A , MartellaC, FelicioniL et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol.23(4), 857–865 (2005).
  • Nie Q , YangX, AnS et al. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) n polymorphism. Eur. J. Cancer47(13), 1962–1970 (2011).
  • Kenny PA , LeeGY, BissellMJ. Targeting the tumor microenvironment. Front. Biosci.12, 3468–3474 (2007).
  • Ruckert F , GrutzmannR, PilarskyC. Feedback within the inter-cellular communication and tumorigenesis in carcinomas. PLoS ONE7(5), e36719 (2012).
  • Hynes NE , LaneHA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer5(5), 341–354 (2005).
  • Krause D , van Etten R. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med.353(2), 172–187 (2005).
  • Pao W , ChmieleckiJ. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer10(11), 760–774 (2010).
  • Holbro T , HynesNE. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol.44, 195–217 (2004).
  • Warren CM , LandgrafR. Signaling through ERBB receptors: multiple layers of diversity and control. Cell. Signal.18(7), 923–933 (2006).
  • Olayioye MA , NeveRM, LaneHA, HynesNE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J.19(13), 3159–3167 (2000).
  • Yarden Y , SliwkowskiMX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol.2(2), 127–137 (2001).
  • Scaltriti M , BaselgaJ. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res.12(18), 5268–5272 (2006).
  • Baselga J , SwainSM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer9(7), 463–475 (2009).
  • Mayo C , Bertran-AlamilloJ, Molina-VilaMA, Gimenez-CapitanA, CostaC, RosellR. Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. Pharmacogenomics13(7), 789–802 (2012).
  • Ladanyi M , PaoW. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod. Pathol.21(Suppl. 2), S16–S22 (2008).
  • Hirsch FR , JännePA, EberhardtWE et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J. Thorac. Oncol. 8(3), 373–384 (2013).
  • Kranenburg O . The KRAS oncogene: past, present, and future. Biochim. Biophys. Acta1756(2), 81–82 (2005).
  • Loriot Y , MordantP, DeutschE, OlaussenKA, SoriaJC. Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat. Rev. Clin. Oncol.6(9), 528–534 (2009).
  • Schubbert S , ShannonK, BollagG. Hyperactive ras in developmental disorders and cancer. Nat. Rev. Cancer7(4), 295–308 (2007).
  • Roberts PJ , DerCJ. Targeting the Raf–MEK–ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene26(22), 3291–3310 (2007).
  • Meylan E , DooleyAL, FeldserDM et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462(7269), 104–107 (2009).
  • Aviel-Ronen S , BlackhallF, ShepherdF, TsaoM. K-ras mutations in non-small-cell lung carcinoma: a review. Clin. Lung Cancer8(1), 30–38 (2006).
  • Marks JL , BroderickS, ZhouQ et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J. Thorac. Oncol. 3(2), 111–116 (2008).
  • Raponi M , WinklerH, DracopoliNC. KRAS mutations predict response to EGFR inhibitors. Curr. Opin. Pharmacol.8(4), 413–418 (2008).
  • Martinelli E , TroianiT, D‘AiutoE et al. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int. J. Cancer 133(9), 2089–2101 (2013).
  • Jänne PA , ShawAT, PereiraJR et al. Selumetinib plus docetaxel for KRAS mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, Phase 2 study. Lancet Oncol. 14(1), 38–47 (2013).
  • Alamgeer M , GanjuV, WatkinsDN. Novel therapeutic targets in non-small cell lung cancer. Curr. Opin. Pharmacol.13(3), 394–401 (2013).
  • Soda M , ChoiYL, EnomotoM et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561–566 (2007).
  • Mano H . Non-solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer. Cancer Sci.99(12), 2349–2355 (2008).
  • Horn L , PaoW. EML4–ALK: honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol.27(26), 4232–4235 (2009).
  • Soda M , TakadaS, TakeuchiK et al. A mouse model for EML4–ALK-positive lung cancer. Proc. Natl Acad. Sci. USA 105(50), 19893–19897 (2008).
  • Choi YL , SodaM, YamashitaY et al. EML4–ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363(18), 1734–1739 (2010).
  • Camidge DR , KonoSA, FlaccoA et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 16(22), 5581–5590 (2010).
  • Inamura K , TakeuchiK, TogashiY et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol. 22(4), 508–515 (2009).
  • Hanahan D , WeinbergRA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
  • Kono SA , HeasleyLE, DoebeleRC, CamidgeDR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr. Cancer Drug Targets12(2), 107–123 (2012).
  • Folkman J . What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82(1), 4–6 (1990).
  • Macchiarini P , FontaniniG, DulmetE et al. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann. Thorac. Surg. 57(6), 1534–1539 (1994).
  • Shibuya M , Claesson-WelshL. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res.312(5), 549–560 (2006).
  • Kut C , Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br. J. Cancer97(7), 978–985 (2007).
  • Fukumura D , XavierR, SugiuraT et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94(6), 715–725 (1998).
  • Liang WC , WuX, PealeFV et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281(2), 951–961 (2006).
  • Reck M , von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol.27(8), 1227–1234 (2009).
  • Reck M , von Pawel J, Zatloukal P et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised Phase III trial (AVAiL). Ann. Oncol.21(9), 1804–1809 (2010).
  • Bieniasz M , OszajcaK, EusebioM, KordiakJ, BartkowiakJ, SzemrajJ. The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer66(3), 319–326 (2009).
  • Johnson DH , FehrenbacherL, NovotnyWF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184–2191 (2004).
  • Kerbel R . Tumor angiogenesis. N. Engl. J. Med.358(19), 2039–2049 (2008).
  • Thomas M , AugustinHG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis12(2), 125–137 (2009).
  • de Mello RA , CostaBM, ReisRM, HespanholV. Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent Pat. Anticancer Drug Discov.7(1), 118–131 (2012).
  • Bergers G , HanahanD. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer8(8), 592–603 (2008).
  • Behrens C , LinHY, LeeJJ et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin. Cancer Res. 14(19), 6014–6022 (2008).
  • Takeda M , AraoT, YokoteH et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin. Cancer Res. 13(10), 3051–3057 (2007).
  • Eswarakumar VP , LaxI, SchlessingerJ. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev.16(2), 139–149 (2005).
  • Grose R , DicksonC. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev.16(2), 179–186 (2005).
  • Marek L , WareKE, FritzscheA et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol. 75(1), 196–207 (2009).
  • Thomson S , PettiF, Sujka-KwokI, EpsteinD, HaleyJD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin. Exp. Metastasis25(8), 843–854 (2008).
  • Martini F , FerroniP, GuadagniF et al. Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients. Anticancer Res. 25(1B), 403–407 (2005).
  • Mochizuki S , SoejimaK, ShimodaM et al. Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand Factor. J. Natl Cancer Inst. 104(12), 906–922 (2012).
  • Hsu YL , KuoPL, LinCC. Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci.75(19), 2303–2316 (2004).
  • Roa W , ChenH, AlexanderA et al. Enhancement of radiation sensitivity with BH3I-1 in non-small cell lung cancer. Clin. Invest. Med. 28(2), 55–63 (2005).
  • Galluzzi L , MorselliE, KeppO, TajeddineN, KroemerG. Targeting p53 to mitochondria for cancer therapy. Cell Cycle7(13), 1949–1955 (2008).
  • Groeger AM , EspositoV, de Luca A et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology44(1), 54–63 (2004).
  • Shimizu S , TakeharaT, HikitaH et al. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J. Hepatol. 52(5), 698–704 (2010).
  • Gabellini C , CastelliniL, TrisciuoglioD, KrachtM, ZupiG, del Bufalo D. Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma. J. Neurochem.107(3), 871–882 (2008).
  • Mirabello L , YuK, KraftP et al. The association of telomere length and genetic variation in telomere biology genes. Hum. Mutat. 31(9), 1050–1058 (2010).
  • Zienolddiny S , SkaugV, LandvikNE et al. The TERT–CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis 30(8), 1368–1371 (2009).
  • James MA , WenW, WangY et al. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS ONE 7(6), e36116 (2012).
  • de Mello RA , FerreiraM, Soares-PiresF et al. The impact of polymorphic variations in the 5p15, 6p12, 6p21 and 15q25 loci on the risk and prognosis of Portuguese patients with non-small cell lung. PLoS ONE 8(9), e72373 (2013).
  • Wang X , WangY, ChengJ, HaM. Association of thymidylate synthase gene 3´-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J. Biomed. Sci.20, 5 (2013).
  • Collins AV , BrodieDW, GilbertRJ et al. The interaction properties of costimulatory molecules revisited. Immunity 17(2), 201–210 (2002).
  • Schreiber RD , OldLJ, SmythMJ. Cancer immunoediting: integrating immunity‘s roles in cancer suppression and promotion. Science331(6024), 1565–1570 (2011).
  • Pentcheva-Hoang T , CorseE, AllisonJP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol. Rev.229(1), 67–87 (2009).
  • Grosso JF , Jure-KunkelMN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun.13, 5 (2013).
  • Egen JG , KuhnsMS, AllisonJP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol.3(7), 611–618 (2002).
  • O‘Day SJ , HamidO, UrbaWJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer110(12), 2614–2627 (2007).
  • de Mello RA , AraújoA. Anaplastic lymphoma kinase gene rearrangement and non-small cell lung cancer management: a step forward in personalized therapy. Clinics (Sao Paulo)68(5), 726 (2013).
  • de Mello RA , LuisM, AraújoA, ReisRM, HespanholV. The Role Of Genetic Polymorphisms In The Angiogenesis Pathway And Non-Small Cell Lung Cancer Tumor Behavior: Implications In Risk Assessment And Clinical Outcome. In: Biochemical Basis and Therapeutic Implications of Angiogenesis. Mehta JL, Dhalla NS (Eds). Springer, NY, USA, 381–403 (2013).
  • Kosaka T , YatabeY, EndohH, KuwanoH, TakahashiT, MitsudomiT. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res.64(24), 8919–8923 (2004).
  • Maemondo M , InoueA, KobayashiK et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380–2388 (2010).
  • Mok T , WuY, ThongprasertS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009).
  • Kris M , NataleR, HerbstR et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16), 2149–2158 (2003).
  • Pérez-Soler R , ChachouaA, HammondL et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3238–3247 (2004).
  • Mitsudomi T , MoritaS, YatabeY et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121–128 (2010).
  • Zhou C , WuY, ChenG et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735–742 (2011).
  • Herbst R , PragerD, HermannR et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892–5899 (2005).
  • Cappuzzo F , CiuleanuT, StelmakhL et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase 3 study. Lancet Oncol. 11(6), 521–529 (2010).
  • Gridelli C , CiardielloF, GalloC et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J. Clin. Oncol. 30(24), 3002–3011 (2012).
  • Pérol M , ChouaidC, PérolD et al. Randomized, Phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 130(28), 3516–3524 (2012).
  • Govindan R , BogartJ, StinchcombeT et al. Randomized Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and leukemia group B trial 30407. J. Clin. Oncol. 29(23), 3120–3125 (2011).
  • Li Y , SunZ, CunninghamJM et al. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin. Cancer Res. 17(11), 3830–3840 (2011).
  • O‘Byrne KJ , GatzemeierU, BondarenkoI et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the Phase 3 FLEX study. Lancet Oncol. 12(8), 795–805 (2011).
  • Pirker R , FilipitsM. Cetuximab in non-small-cell lung cancer. Transl. Lung Cancer Res.1(1), 54–60 (2012).
  • Pirker R , PereiraJR, von Pawel J et al.EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the Phase 3 FLEX study. Lancet Oncol.13(1), 33–42 (2011).
  • Pirker R , PereiraJR, SzczesnaA et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525–1531 (2009).
  • Miller VA , HirshV, CadranelJ et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol. 13(5), 528–538 (2012).
  • Hirsh V , CadranelJ, CongXJ et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized Phase IIb/III trial (LUX-Lung 1). J. Thorac. Oncol. 8(2), 229–237 (2013).
  • Kwak EL , BangYJ, CamidgeDR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693–1703 (2010).
  • Rodig SJ , ShapiroGI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr. Opin. Investig. Drugs11(12), 1477–1490 (2010).
  • Shaw AT , YeapBY, SolomonBJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12(11), 1004–1012 (2011).
  • Camidge DR , BangYJ, KwakEL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a Phase 1 study. Lancet Oncol. 13(10), 1011–1019 (2012).
  • Dahlberg S , SandlerA, BrahmerJ, SchillerJ, JohnsonD. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J. Clin. Oncol.28(6), 949–954 (2010).
  • Méndez-Vidal MJ , Martínez Ortega E, Montesa Pino Á, Pérez Valderrama B, Viciana R. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Cancer Metastasis Rev.31(Suppl. 1), S19–S27 (2012).
  • Socinski MA , NovelloS, BrahmerJ et al. Multicenter, Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol. 26(4), 650–656 (2008).
  • Gervais R , HainsworthJD, BlaisN et al. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 74(3), 474–480 (2011).
  • Scagliotti GV , KrzakowskiM, SzczesnaA et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a Phase III trial. J. Clin. Oncol. 30(17), 2070–2078 (2012).
  • Adjei A , MolinaJ, MandrekarS et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small-cell lung cancer. Clin. Cancer Res. 13(9), 2684–2691 (2007).
  • Blumenschein G , GatzemeierU, FossellaF et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J. Clin. Oncol. 27(26), 4274–4280 (2009).
  • Wilhelm SM , CarterC, TangL et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099–7109 (2004).
  • Lind J , DingemansA, GroenH et al. A multicenter Phase II study of erlotinib and sorafenib in chemotherapy-naïve patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16(11), 3078–3087 (2010).
  • Hanna N , von Pawel J, Reck M, Scagliotti G. Carboplatin/paclitaxel with/without sorafenib in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from a randomized Phase III trial (ESCAPE). J. Thorac. Oncol.3, S268 (2008).
  • Paz-Ares LG , BiesmaB, HeigenerD et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 30(25), 3084–3092 (2012).
  • Spigel DR , BurrisHA 3rd, Greco FA et al. Randomized, double-blind, placebo-controlled, Phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol.29(18), 2582–2589 (2011).
  • de Mello RA , AraújoA. Epidermal growth factor receptor mutation frequency and non-small cell lung cancer management: implication for treatment choices. Clinics (Sao Paulo)67(11), 1349 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.